Literature DB >> 22714621

Dermatomyositis presenting as a paraneoplastic syndrome due to underlying breast cancer.

Nicole P Sandhu1, Shaheen Zakaria, Amy C Degnim, Judy C Boughey.   

Abstract

Breast cancer most often presents as a palpable mass or with an abnormal mammogram. Much less commonly, breast cancer may present as a paraneoplastic syndrome. Dermatomyositis (DM) is a rare disease most often considered a complement-mediated idiopathic inflammatory myopathy manifested by classic skin findings and proximal muscle weakness. However, DM may also be due to a paraneoplastic syndrome associated with an underlying malignancy. The authors present a case report of a woman with presumed contact dermatitis who was diagnosed with breast cancer in the setting of progressive fatigue and muscle weakness. DM was subsequently diagnosed. Treatment of DM simultaneous with treatment of the breast cancer led to regression of DM. The diagnosis of DM in an adult should raise suspicion of an underlying malignancy. Breast cancer is a common disease that may rarely present with uncommon features that may divert attention from the underlying malignancy.

Entities:  

Mesh:

Year:  2011        PMID: 22714621      PMCID: PMC3062365          DOI: 10.1136/bcr.10.2010.3416

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  11 in total

Review 1.  Polymyositis and dermatomyositis (first of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-13       Impact factor: 91.245

2.  High incidence of malignancies in patients with dermatomyositis and polymyositis: an 11-year analysis.

Authors:  C R Maoz; P Langevitz; A Livneh; Z Blumstein; M Sadeh; I Bank; H Gur; M Ehrenfeld
Journal:  Semin Arthritis Rheum       Date:  1998-04       Impact factor: 5.532

Review 3.  Dermatomyositis and malignancy. A review of the literature.

Authors:  B E Barnes; B Mawr
Journal:  Ann Intern Med       Date:  1976-01       Impact factor: 25.391

4.  Dermatomyositis associated with breast cancer.

Authors:  Dimitrios Pectasides; Maria Koumpou; Asimina Gaglia; Melina Pectasides; V Lambadiari; E Lianos; G Papaxoinis; Th Economopoulos
Journal:  Anticancer Res       Date:  2006 May-Jun       Impact factor: 2.480

5.  Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study.

Authors:  C L Hill; Y Zhang; B Sigurgeirsson; E Pukkala; L Mellemkjaer; A Airio; S R Evans; D T Felson
Journal:  Lancet       Date:  2001-01-13       Impact factor: 79.321

6.  Flare-up of dermatomyositis along with recurrence of breast cancer.

Authors:  Tomo Osako; Yoshinori Ito; Akeshi Morimatsu; Keiichiro Tada; Naoki Sakurai; Shunji Takahashi; Futoshi Akiyama; Takuji Iwase; Kiyohiko Hatake
Journal:  Breast J       Date:  2007 Mar-Apr       Impact factor: 2.431

7.  Dermatomyositis/polymyositis associated with internal malignancy: a consequence of how neoplasms alter generalized extracellular matrix in the host.

Authors:  O J Stone
Journal:  Med Hypotheses       Date:  1993-07       Impact factor: 1.538

8.  Breast cancer and second primary ovarian cancer in dermatomyositis.

Authors:  N Voravud; M Dimopoulos; G Hortobagyi; M Ross; R Theriault
Journal:  Gynecol Oncol       Date:  1991-12       Impact factor: 5.482

9.  The relationship of dermatomyositis and polymyositis to internal malignancy.

Authors:  J P Callen; J F Hyla; G G Bole; D R Kay
Journal:  Arch Dermatol       Date:  1980-03

10.  Risk of cancer in patients with dermatomyositis or polymyositis, and follow-up implications: a Scottish population-based cohort study.

Authors:  D Stockton; V R Doherty; D H Brewster
Journal:  Br J Cancer       Date:  2001-07-06       Impact factor: 7.640

View more
  9 in total

1.  Breast cancer and dermatomyositis: a case study and literature review.

Authors:  E Hendren; O Vinik; H Faragalla; R Haq
Journal:  Curr Oncol       Date:  2017-10-25       Impact factor: 3.677

2.  Paraneoplastic Dermatomyositis with Cutaneous and Myopathic Disease Responsive to Adrenocorticotropic Hormone Therapy.

Authors:  Marisa Wolff; Christopher Mancuso; Karan Lal; Damian Dicostanzo; Charles Gropper
Journal:  J Clin Aesthet Dermatol       Date:  2017-01-01

3.  Dermatomyositis presenting as a paraneoplastic syndrome with resolution of symptoms following surgical management of underlying breast malignancy.

Authors:  Xuan Luu; Samantha Leonard; Kathie-Ann Joseph
Journal:  J Surg Case Rep       Date:  2015-07-07

4.  A rare case of severe myositis as paraneoplastic syndrome on breast cancer.

Authors:  Leonardo Pires Novais Dias; Ana Luiza Antunes Faria; Maissa Marçola Scandiuzzi; Claudia Luci dos Santos Inhaia; Jorge Yoshinori Shida; Luiz Henrique Gebrim
Journal:  World J Surg Oncol       Date:  2015-04-01       Impact factor: 2.754

5.  A Recurrent Episode of Dermatomyositis Associated with Papillary Thyroid Cancer.

Authors:  Vijay Gopal Eranki
Journal:  Case Rep Endocrinol       Date:  2017-07-19

6.  Triple-Negative Breast Cancer with Dermatomyositis: A Case Report and Literature Review.

Authors:  Xiao Chen; Aoxiang Chen; Chaoqi Liu; Bin Zhang
Journal:  Cancer Manag Res       Date:  2022-02-15       Impact factor: 3.989

7.  A Case of Pathological Complete Response and Resolution of Dermatomyositis Following Neoadjuvant Chemotherapy in HER2-Positive Early Breast Cancer.

Authors:  Marta Piras; Martina Panebianco; Matteo Garibaldi; Michela Roberto; Gioia Merlonghi; Patrizia Pellegrini; Paolo Marchetti
Journal:  Curr Oncol       Date:  2021-05-24       Impact factor: 3.677

8.  Inflammatory breast cancer associated with amyopathic dermatomyositis: a case report.

Authors:  Gaku Inaguma; Akihiko Shimada; Junya Tsunoda; Tomohiko Matsuzaki; Tomohiko Nishi; Hiroaki Seki; Hidetoshi Matsumoto
Journal:  Surg Case Rep       Date:  2020-11-11

9.  Dermatomyositis Related Paraneoplastic Encephalitis Presenting as Terminal Delirium in the Palliative Care Unit - A Case Report.

Authors:  Kelvin Lou; Shikha Minhas; Shalini Nayar
Journal:  J Palliat Care       Date:  2022-01-24       Impact factor: 1.980

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.